Literature DB >> 30686694

Opioid creep in burn center discharge regimens: Doubled amounts and complexity of narcotic prescriptions over seven years.

Andy Tully1, Lillian Anderson2, William Adams3, Michael J Mosier1.   

Abstract

Prescription opioid misuse is an epidemic international health crisis. Although burn providers are increasingly mindful of balancing pain relief with risk of opioid dependence, several burn centers have noticed their patients are still receiving an increased amount of opioids, termed "opioid creep." We examined discharge narcotic prescriptions at a single burn center in the Midwest United States and found that patients discharged in 2015 received nearly twice the amount of narcotics (mean=600 morphine equivalents [ME]) than those discharged in 2008 (mean=350 ME), with a significantly increased likelihood of a more complex narcotic discharge regimen. The increase in ME remained significant even after controlling for age, burn size, intensive care unit stay, discharge day, substance abuse, comorbidity status, insurance, language, race, and ethnicity. The data do not clearly explain such a significant increase. Although such increase in opioid prescription is undesirable, so too is regression to historical under-treatment of burn pain. Protocoled pain-management order sets on admission and discharge, as well as incorporation of alternatives adjuncts to lessen pain, may allow for better pain control with less opioid misuse.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Acute pain management opoid; Burn pain; Burns; Prescription opioid

Mesh:

Substances:

Year:  2019        PMID: 30686694     DOI: 10.1016/j.burns.2018.08.004

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  1 in total

1.  US national trends in prescription opioid use after burn injury, 2007 to 2017.

Authors:  Efstathia Polychronopoulou; Mukaila A Raji; Steven E Wolf; Yong-Fang Kuo
Journal:  Surgery       Date:  2021-01-17       Impact factor: 4.348

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.